Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.36
-8.1%		$0.33
$0.00
▼
$2.85
$14.63M-1.8231,222 shs100 shs
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.10
$0.10
$0.09
▼
$1.50
$15.86M2.087.28 million shsN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.08
-0.9%		$0.98
$0.75
▼
$2.29
$16.50M0.55188,730 shs57,265 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$1.65
-0.3%		$1.94
$1.55
▼
$4.59
$4.19M-0.9712,376 shs3,387 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-8.05%+13.84%+8.67%-4.37%-85.42%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%0.00%0.00%0.00%-79.87%
BioCardia, Inc. stock logo
BCDA
BioCardia
-0.92%-6.09%+13.68%+4.85%-47.06%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-0.30%+2.49%-18.56%-27.85%-26.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$0.36
-8.1%		$0.33
$0.00
▼
$2.85
$14.63M-1.8231,222 shs100 shs
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.10
$0.10
$0.09
▼
$1.50
$15.86M2.087.28 million shsN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
$1.08
-0.9%		$0.98
$0.75
▼
$2.29
$16.50M0.55188,730 shs57,265 shs
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
$1.65
-0.3%		$1.94
$1.55
▼
$4.59
$4.19M-0.9712,376 shs3,387 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-8.05%+13.84%+8.67%-4.37%-85.42%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%0.00%0.00%0.00%-79.87%
BioCardia, Inc. stock logo
BCDA
BioCardia
-0.92%-6.09%+13.68%+4.85%-47.06%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-0.30%+2.49%-18.56%-27.85%-26.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
1.00
SellN/AN/A
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.67
Reduce$1.00870.87% Upside
BioCardia, Inc. stock logo
BCDA
BioCardia
2.00
Hold$25.002,214.81% Upside
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest TCRT, BCDA, ANEB, and APLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/17/2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
7/31/2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/9/2026
BioCardia, Inc. stock logo
BCDA
BioCardia
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$25.00
(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.28 per shareN/A
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$1M15.86N/AN/A$0.49 per share0.21
BioCardia, Inc. stock logo
BCDA
BioCardia
$60K272.52N/AN/A$0.18 per share6.00
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/A$0.26 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%9/23/2026 (Estimated)
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/A
BioCardia, Inc. stock logo
BCDA
BioCardia
-$8.23M-$0.64N/AN/AN/AN/A-569.36%-183.15%11/11/2026 (Estimated)
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
-$4.18M-$1.91N/AN/AN/AN/A-232.60%-158.99%11/17/2026 (Estimated)

Latest TCRT, BCDA, ANEB, and APLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/23/2026Q4 2026
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.10N/AN/AN/AN/AN/A
8/14/2026Q2 2026
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A-$0.41N/A-$0.41N/AN/A
8/12/2026Q2 2026
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.18-$0.13+$0.05-$0.13N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
6.24
6.24
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
0.96
0.96
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
2.09
2.09
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
98.31%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
27.72%

Insider Ownership

CompanyInsider Ownership
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.60%
BioCardia, Inc. stock logo
BCDA
BioCardia
17.40%
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
16.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
440.79 million7.91 millionNot Optionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30153.96 million151.50 millionOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
4015.14 million12.51 millionOptionable
Alaunos Therapeutics, Inc. stock logo
TCRT
Alaunos Therapeutics
402.54 million2.13 millionNo Data

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
June 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/alaunos-reports-new-preclinical-aln1003-data-showing-lower-liver-weight-after-adjustment-for-body-fat-percentage-in-48-day-dio-mouse-study-1036282571
Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
May 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68596910-alaunos-therapeutics-inc-alaunos-reports-broad-metabolic-improvements-with-aln1003-in-obese-mouse-studies-399.htm
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers
May 26, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/alaunos-reports-positive-preclinical-obesity-drug-results-across-weight-liver-insulin-markers/ar-AA247lNo
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301281/18421/en/alaunos-reports-broad-metabolic-improvements-with-aln1003-in-obese-mouse-studies.html
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296589/18421/en/alaunos-reports-preclinical-aln1003-data-showing-effects-on-insulin-resistance-related-biomarkers-and-liver-histology-in-diet-induced-obesity-models.html
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
March 2, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/03/50973478/weight-loss-data-from-obese-mice-looks-promising-for-alaunos-therapeutics-but-shares-drop?utm_source=snapi
Alaunos Reports Positive Preclinical Data for Obesity Candidate
March 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alaunos-reports-positive-preclinical-data-for-obesity-candidate?utm_source=marketbeat.com&utm_medium=referral
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
March 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/02/3247189/18421/en/alaunos-therapeutics-announces-positive-preclinical-proof-of-concept-data-for-aln1003-a-differentiated-non-hormonal-oral-treatment-for-obesity-and-related-metabolic-disorders.html
Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer
December 23, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alaunos-therapeutics-reaches-settlement-with-md-anderson-cancer?utm_source=marketbeat.com&utm_medium=referral
Alaunos Therapeutics files to sell 327,740 shares of common for holders
October 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/alaunos-therapeutics-files-to-sell-327-740-shares-of-common-for-holders/ar-AA1OYpx1
Alaunos Therapeutics files $50M mixed securities shelf
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/alaunos-therapeutics-files-50m-mixed-securities-shelf/ar-AA1KXkeu
Alaunos Therapeutics files $50M mixed securities shelf
August 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/alaunos-therapeutics-files-50m-mixed-securities-shelf/ar-AA1KXkeu
Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/alaunos-therapeutics-innovative-glioblastoma-study-completes-market-implications/ar-AA1KoUIY
Alaunos Therapeutics Appoints Holger Weis as New CEO
July 25, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TCRT/pressreleases/33209049/alaunos-therapeutics-appoints-holger-weis-as-new-ceo/
Alaunos Therapeutics Taps Board Member Weis as Next CEO
July 2, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/alaunos-therapeutics-taps-board-member-weis-as-next-ceo-fa9c1924
Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance
June 26, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TCRT/financials/
Alaunos Therapeutics Raises $850,000 in Private Offering
June 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alaunos-therapeutics-raises-850000-in-private-offering?utm_source=marketbeat.com&utm_medium=referral
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar
June 24, 2025  |  morningstar.comM
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
June 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/23/3103328/18421/en/alaunos-therapeutics-announces-2-0-million-registered-direct-offering.html
Alaunos Therapeutics Amends Warrant Agreement with Mast Hill
June 10, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alaunos-therapeutics-amends-warrant-agreement-with-mast-hill?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$0.36 -0.03 (-8.05%)
As of 09/4/2026 03:43 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.10 0.00 (0.00%)
As of 09/3/2026

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

BioCardia stock logo

BioCardia NASDAQ:BCDA

$1.08 -0.01 (-0.92%)
As of 09/4/2026 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Alaunos Therapeutics stock logo

Alaunos Therapeutics NASDAQ:TCRT

$1.64 -0.01 (-0.30%)
As of 09/4/2026 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas